Compare HubSpot Inc (HUBS) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HubSpot Inc vs Travere Therapeutics Inc. Common Stock — how do they compare? HubSpot Inc trades at $227.11 (market cap $11.28B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $5.02B). The key difference: HubSpot Inc is far larger — about 2.2× Travere Therapeutics Inc. Common Stock's market cap, and Travere Therapeutics Inc. Common Stock is trading nearer its 52-week high, HubSpot Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold HubSpot Inc for 78 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| HUBS | TVTX | |
|---|---|---|
Market Cap | $11.28B | $5.02B |
Volume | 1,027,877.02 | 2,060,842 |
Sector | Technology | Health |
52-Week High | $494.58 | $67.52 |
52-Week Low | $170.39 | $26.79 |
Typical Hold Time | 78 Days | 0 Days |
Enterprise Value | $10.18B | $5.15B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HubSpot (HUBS) trades at $221.02, down 1.05% on the day, with a neutral technical signal. The company shows strong revenue growth, reaching $3.13B in 2025, and has beaten earnings estimates for three consecutive quarters. Recent news highlights its AI strategy and partnership with OpenAI, aiming to boost margins. Cash flow from operations is robust at $760.72M, though valuation ratios like a P/E of 80.51 remain elevated.
The outlook is cautiously optimistic, with a consensus price target of $244.09 implying upside potential. Key opportunities include AI-driven growth and margin expansion, but risks involve high valuation, competitive pressures, and sensitivity to economic cycles. Analyst sentiment is predominantly buy-rated, supporting a positive medium-term view.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About HubSpot Inc
HubSpot provides a cloud-based marketing, sales, and customer service software platform referred to as the growth platform. The applications are available ala carte or packaged together. HubSpot's mission is to help companies grow better and has expanded from its initial focus on inbound marketing to embrace marketing, sales, and service more broadly. The company was founded in 2006, completed its initial public offering in 2014, and is headquartered in Cambridge, Massachusetts.
Read more on HUBS →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
